Completed PHASE2 INTERVENTIONAL 2-arm NCT00892970

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period

Sponsor: Merck Sharp & Dohme LLC

Interventions Azithromycin ophthalmic solution, 1% Placebo

Updated 9 times since 2017 Last updated: Sep 20, 2011 Started: Apr 30, 2009 Primary completion: Jan 31, 2010 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00892970, this PHASE2 trial focuses on Blepharitis and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 9 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2022 — Jul 2024 [monthly]

Completed PHASE2
Apr 2022 — Jun 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Artesia, United States , Austin, United States , Azusa, United States , Baltimore, United States , Boston, United States , Boynton Beach, United States , Charlotte, United States , Cleveland, United States , Fort Myers, United States , Glenview, United States and 22 more locations